查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446443

经皮给药系统市场规模、份额、趋势分析报告：按技术、按应用、按地区、细分市场预测，2024-2030

Transdermal Drug Delivery Systems Market Size, Share & Trends Analysis Report By Technology (Iontophoresis, Mechanical Arrays), By Application, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

经皮给药系统市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球经皮给药系统市场规模预计将达到1,450.4亿美元，复合年增长率为11.9%。

经皮吸收贴片的接受度不断提高，特别是对于糖尿病等需要持续每日註射胰岛素剂量的疾病，预计将推动经皮给药系统领域的市场成长。

此外，糖尿病患者需要定期注射胰岛素，传统上透过注射给药，这可能会引起不适并增加疾病传播的风险。因此，经皮递送系统似乎是递送胰岛素的更有吸引力的选择。促进市场成长的另一个重要因素是对无痛给药的需求不断增长。持续注射胰岛素会导致不适和慢性疾病。经皮吸收贴片可以解决这些问题，因为它们提供了一种更舒适、更有效的胰岛素输送方法。

此外，随着糖尿病、心臟病和疼痛相关问题等慢性疾病在世界各地变得越来越普遍，对有效且患者友善的药物传递方法的需求日益增长。例如，根据美国心臟协会2022年全球疾病负担报告，死亡率为239.8，盛行率为每10万人7354.1。经皮给药系统具有多种优点，包括非侵入性、受控药物释放、提高患者依从性和最小化副作用。对这种用户友好的药物输送系统的需求不断增长，特别是对长期药物的持续管理，正在推动经皮药物输送市场的成长。

经皮给药系统市场报告重点：

  • 2023年，离子电渗透疗法领域占最大市场占有率。这可能是由于使用电流通过皮肤非侵入性地输送药物的有效性。
  • 2023年，由于慢性疾病和创伤（包括关节炎、骨关节炎和整形外科退化性疾病等肌肉骨骼疾病）的盛行率不断增加，疼痛管​​理领域引领了应用领域。这些疾病的日益普及正在促进并推动该领域的发展。
  • 在到 2023 年的预测期内，荷尔蒙应用领域预计将以指数复合年增长率成长。这是由于对方便的荷尔蒙疗法的需求不断增加。经皮给药的功效和简单性使其成为荷尔蒙给药的有吸引力的解决方案。
  • 由于先进的医疗基础设施以及慢性疼痛、中枢神经系统疾病和心血管疾病等目标疾病的高盛行率，北美地区在 2023 年占据最大的市场占有率。
  • 市场参与者已采取多项策略倡议来扩大产品覆盖范围并提高不同地区的可用性。

目录

第一章经皮给药系统市场：调查方法与范围

第二章经皮给药系统市场：执行摘要

  • 市场展望
  • 分部展望
  • 竞争考察

第三章经皮系统市场：变数、趋势、范围

  • 市场体系展望
  • 市场动态
  • 经皮给药系统市场分析工具

第四章经皮给药系统市场：技术评估与趋势分析

  • 定义和范围
  • 2023年及2030年技术市场占有率
  • 细分仪表板
  • 按技术展望分類的全球经皮系统市场
  • 2018年至2030年市场应用与预测及趋势分析

第五章经皮给药系统市场：应用估计与趋势分析

  • 定义和范围
  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 全球经皮给药系统市场应用前景展望
  • 2018年至2030年市场应用与预测及趋势分析

第六章经皮给药系统市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
    • 创新者
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Novartis AG
    • Johnson &Johnson
    • Mylan Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • AbbVie
    • Grunenthal
    • Skyepharma
    • 3M Company
    • Noven Pharmaceuticals, Inc.
    • 4P Therapeutics, LLC
    • Hisamitsu Pharmaceutical co. Inc
Product Code: GVR-1-68038-062-0

Transdermal Drug Delivery Systems Market Growth & Trends:

The global transdermal drug delivery systems market size is anticipated to reach to reach USD 145.04 billion by 2030, expanding at a CAGR of 11.9%, based on a new report by Grand View Research, Inc. The growing acceptance of transdermal patches, particularly for conditions like diabetes that necessitate consistent and daily insulin dosage, is projected to drive market growth in the transdermal drug delivery systems sector.

In addition, diabetes patients require regular insulin administration, traditionally done through injections, which can cause discomfort and increase the risk of disease transmission. This makes transdermal drug delivery system will be a more appealing alternative for delivering insulin.Another significant factor contributing to the growth of the market is the rising demand for painless drug delivery. The constant use of injections for insulin administration can lead to discomfort and even chronic diseases. Transdermal patches offer a more comfortable and efficient way of delivering insulin, thus addressing these issues.

Moreover, chronic diseases like diabetes, heart conditions, and pain-related issues become more common globally, there is a greater need for drug delivery methods that are both effective and easy for patients to use. For example, according to the American Heart Association's 2022 report on the Global Burden of Disease, the death rate per 100,000 people was 239.8, while the prevalence rate was 7354.1 per 100,000. Transdermal drug delivery systems come with multiple benefits such as being non-invasive, providing controlled drug release, enhancing patient adherence, and minimizing side effects. This increasing demand for user-friendly drug delivery systems, particularly for the ongoing management of long-term medications, is driving the transdermal drug delivery market growth.

Transdermal Drug Delivery Systems Market Report Highlights:

  • In 2023, the iontophoresis segment accounted for the largest market share. This can be attributed due to its effectiveness in delivering medications non-invasively through the skin using electrical currents
  • In 2023, the pain management segment led the application segment due to the increasing prevalence of chronic diseases and trauma, including musculoskeletal disorders such as arthritis, osteoarthritis, and orthopedic degenerative disorders. The growing prevalence of these conditions is contributing, driving the segment growth
  • The hormone segment is expected to grow at an exponential CAGR during the forecast period in the application segment in 2023. This is due to rising demand for convenient hormone therapies. Transdermal delivery's effectiveness and user-friendliness make it an attractive solution for administering hormones
  • The North American region held the largest market share in 2023 due to advanced healthcare infrastructure and high prevalence of targeted diseases like chronic pain, central nervous system disorders, and cardiovascular diseases in the region
  • Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas

Table of Contents

Chapter 1. Transdermal Drug Delivery Systems Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Technology
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Transdermal Drug Delivery Systems Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Transdermal Drug Delivery Systems Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing adoption of transdermal patches
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. High demand for pain free drug delivery
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of transdermal technology
      • 3.2.2.2. Limited number of approved medications
  • 3.3. Transdermal Drug Delivery System Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Transdermal Drug Delivery Systems Market: Technology Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Electroporation
    • 4.1.2. Radio Frequency
    • 4.1.3. Iontophoresis
    • 4.1.4. Microporation
    • 4.1.5. Thermal
    • 4.1.6. Mechanical arrays
    • 4.1.7. Ultrasound
    • 4.1.8. Others
  • 4.2. Technology Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Transdermal Drug Delivery System Market by Technology Outlook
  • 4.5. Market Application & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Electroporation
      • 4.5.1.1. Market estimates and forecast 2018 - 2030 (Revenue in USD Million)
    • 4.5.2. Radio Frequency
      • 4.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 4.5.3. Iontophoresis
      • 4.5.3.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 4.5.4. Microporation
      • 4.5.4.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 4.5.5. Thermal
      • 4.5.5.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 4.5.6. Mechanical Arrays
      • 4.5.6.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 4.5.7. Ultrasound
      • 4.5.7.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 4.5.8. Others
      • 4.5.8.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)

Chapter 5. Transdermal Drug Delivery System Market: Application Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. CNS
    • 5.1.2. Pain Management
    • 5.1.3. Cardiovascular
    • 5.1.4. Hormone
    • 5.1.5. Immunological
    • 5.1.6. Metabolic
    • 5.1.7. Gastrointestinal
    • 5.1.8. Infection
    • 5.1.9. Cancer
    • 5.1.10. Others
  • 5.2. Application Market Share, 2023 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Global Transdermal Drug Delivery System Market by Application Outlook
  • 5.5. Market Application & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. CNS
      • 5.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.2. Pain Management
      • 5.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.3. Cardiovascular
      • 5.5.3.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.4. Hormone
      • 5.5.4.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.5. Immunological
      • 5.5.5.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.6. Metabolic
      • 5.5.6.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.7. Gastrointestinal
      • 5.5.7.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.8. Infection
      • 5.5.8.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.9. Cancer
      • 5.5.9.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
    • 5.5.10. Others
      • 5.5.10.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)

Chapter 6. Transdermal Drug Delivery System Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Competitive scenario
      • 6.5.1.3. Regulatory framework
      • 6.5.1.4. Reimbursement scenario
      • 6.5.1.5. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Reimbursement scenario
      • 6.5.2.5. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Competitive scenario
      • 6.6.1.3. Regulatory framework
      • 6.6.1.4. Reimbursement scenario
      • 6.6.1.5. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Reimbursement scenario
      • 6.6.2.5. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Reimbursement scenario
      • 6.6.3.5. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Competitive scenario
      • 6.6.4.3. Regulatory framework
      • 6.6.4.4. Reimbursement scenario
      • 6.6.4.5. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Competitive scenario
      • 6.6.5.3. Regulatory framework
      • 6.6.5.4. Reimbursement scenario
      • 6.6.5.5. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Competitive scenario
      • 6.6.6.3. Regulatory framework
      • 6.6.6.4. Reimbursement scenario
      • 6.6.6.5. Norway market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Competitive scenario
      • 6.6.7.3. Regulatory framework
      • 6.6.7.4. Reimbursement scenario
      • 6.6.7.5. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Competitive scenario
      • 6.6.8.3. Regulatory framework
      • 6.6.8.4. Reimbursement scenario
      • 6.6.8.5. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Competitive scenario
      • 6.7.1.3. Regulatory framework
      • 6.7.1.4. Reimbursement scenario
      • 6.7.1.5. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. Reimbursement scenario
      • 6.7.2.5. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Reimbursement scenario
      • 6.7.3.5. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. Reimbursement scenario
      • 6.7.4.5. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Reimbursement scenario
      • 6.7.5.5. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Competitive scenario
      • 6.7.6.3. Regulatory framework
      • 6.7.6.4. Reimbursement scenario
      • 6.7.6.5. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Competitive scenario
      • 6.8.1.3. Regulatory framework
      • 6.8.1.4. Reimbursement scenario
      • 6.8.1.5. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Competitive scenario
      • 6.8.2.3. Regulatory framework
      • 6.8.2.4. Reimbursement scenario
      • 6.8.2.5. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Competitive scenario
      • 6.8.3.3. Regulatory framework
      • 6.8.3.4. Reimbursement scenario
      • 6.8.3.5. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Competitive scenario
      • 6.9.1.3. Regulatory framework
      • 6.9.1.4. Reimbursement scenario
      • 6.9.1.5. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Competitive scenario
      • 6.9.2.3. Regulatory framework
      • 6.9.2.4. Reimbursement scenario
      • 6.9.2.5. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Competitive scenario
      • 6.9.3.3. Regulatory framework
      • 6.9.3.4. Reimbursement scenario
      • 6.9.3.5. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Competitive scenario
      • 6.9.4.3. Regulatory framework
      • 6.9.4.4. Reimbursement scenario
      • 6.9.4.5. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Innovators
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Novartis AG
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Johnson & Johnson
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Mylan Pharmaceuticals, Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Boehringer Ingelheim GmbH
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. AbbVie
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Grunenthal
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Skyepharma
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. 3M Company
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Noven Pharmaceuticals, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. 4P Therapeutics, LLC
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Hisamitsu Pharmaceutical co. Inc
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of Abbreviation
  • Table 3. North America transdermal drug delivery system market, by region, 2018 - 2030 (USD Million)
  • Table 4. North America transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 5. North America transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 6. U.S. transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 7. U.S. transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 8. Canada transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 9. Canada transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 10. Europe transdermal drug delivery system market, by region, 2018 - 2030 (USD Million)
  • Table 11. Europe transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 12. Europe transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 13. Germany transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 14. Germany transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 15. UK transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 16. UK transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 17. France transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 18. France transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 19. Italy transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 20. Italy transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 21. Spain transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 22. Spain transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 23. Denmark transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 24. Denmark transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 25. Sweden transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 26. Sweden transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 27. Norway transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 28. Norway transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 29. APAC transdermal drug delivery system market, by region, 2018 - 2030 (USD Million)
  • Table 30. APAC transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 31. APAC transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 32. Japan transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 33. Japan transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 34. India transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 35. India transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 36. China transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 37. China transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 38. South Korea transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 39. South Korea transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 40. Thailand transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 41. Thailand transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 42. Australia transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 43. Australia transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 44. Latin America transdermal drug delivery system market, by region, 2018 - 2030 (USD Million)
  • Table 45. Latin America transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 46. Latin America transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 47. Brazil transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 48. Brazil transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 49. Mexico transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 50. Mexico transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 51. Argentina transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 52. Argentina transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 53. Middle East and Africa transdermal drug delivery system market, by region, 2018 - 2030 (USD Million)
  • Table 54. Middle East and Africa transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 55. Middle East and Africa transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 56. South Africa transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 57. South Africa transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 58. Saudi Arabia transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 59. Saudi Arabia transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 60. UAE transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 61. UAE transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)
  • Table 62. Kuwait transdermal drug delivery system market, by technology, 2018 - 2030 (USD Million)
  • Table 63. Kuwait transdermal drug delivery system market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig 1. Transdermal drug delivery system segmentation
  • Fig 2. Market research process
  • Fig 3. Information procurement process
  • Fig 4. Primary research pattern
  • Fig 5. Transdermal drug delivery system snapshot, 2023 (USD Million)
  • Fig 6. Segment snapshot, USD Million
  • Fig 7. Competitive landscape snapshot
  • Fig 8. Penetration & growth prospect mapping, by product
  • Fig 9. Market driver analysis (Current & future impact)
  • Fig 10. Market restraint analysis (Current & future impact)
  • Fig 11. Transdermal drug delivery system market, technology outlook key takeaways (USD Million)
  • Fig 12. Transdermal drug delivery system: technology movement analysis (USD Million), 2023 & 2030
  • Fig 13. Electroporation market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 14. Radio frequency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 15. Iontophoresis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 16. Microporation market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 17. Thermal market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 18. Mechanical arrays market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 19. Ultrasound market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 20. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 21. Transdermal drug delivery systems market: application movement analysis (USD Million), 2023 & 2030
  • Fig 22. CNS market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 23. Pain Management market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 24. Cardiovascular market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 25. Hormone market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 26. Immunological market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 27. Metabolic market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 28. Gastrointestinal market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 29. Infection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 30. Cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 31. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 32. Transdermal drug delivery system market: Regional key takeaways (USD Million)
  • Fig 33. Transdermal drug delivery system market: Regional outlook, 2023 & 2030, USD Million
  • Fig 34. North America transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 35. U.S. transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 36. Canada transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 37. Europe transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 38. UK transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 39. Germany transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 40. France transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 41. Spain transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 42. Italy transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 43. Sweden transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 44. Norway transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 45. Denmark transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 46. Asia Pacific transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 47. China transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 48. Japan transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 49. India transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 50. South Korea transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 51. Australia transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 52. Thailand transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 53. Latin America transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 54. Brazil transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 55. Mexico transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 56. Argentina transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 57. Middle East and Africa transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 58. South Africa transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 59. Saudi Arabia transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 60. UAE transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 61. Kuwait transdermal drug delivery system market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig 62. List of key emerging company's/technology disruptors/innovators